Eli Lilly

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly’s migraine drug Emgality infringed three patents related to Teva’s rival drug Ajovy.

The drug candidate, olezarsen, showed statistically significant reduction in levels of triglyceride compared to placebo, as well as showed a 100% reduction in inflammation of the pancreas.

Contaminated cough syrup trial, Tashkent

The U.S. FDA is cracking down on lax testing practices by dozens of makers of healthcare products following hundreds of deaths overseas from contaminated cough syrups, a Reuters review of regulatory alerts found.

Novartis, California

The Swiss pharma is one step closer to bringing Lutathera into the front-line setting, with data from the Phase III NETTER-2 study showing that the radiotherapy met its primary endpoint.

Takeda

The Japanese multinational pharma is pledging up to $580 million in a development and commercialization deal with AcuraStem for the latter’s PIKFYVE program for amyotrophic lateral sclerosis.

Moderna

The company supplied its COVID vaccines to the EU during the pandemic, but the contract for its Omicron-adjusted vaccines ended in August last year and was not renewed.

With this deal, expected to close by the end of the year, Alfasigma aims to expand its treatment portfolio related to liver diseases and digestive system disorders.

European Union flag

The move underscores increasing regulatory scrutiny on both sides of the Atlantic of the pharmaceutical industry to ensure that companies continue to innovate and offer products and services at affordable prices without being squeezed out by bigger rivals.

Syneos Health

The industry veteran will play a critical role in leading global clinical operations, cultivating site relationships, empowering patients and shaping innovative clinical trial solutions.

Drugmaker Scynexis said on Monday it would voluntarily recall its antifungal drug Brexafemme from the market and put a temporary hold on studies of the therapy due to the potential risk of cross contamination with another compound.